Intrinsic Value of S&P & Nasdaq Contact Us

Pardes Biosciences, Inc. PRDS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Pardes Biosciences, Inc. (PRDS) .

Criteria proven by this page:

  • VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 25/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
26/100
SG Score
View full scorecard →
VALUE
N/A
No coverage
FUTURE
20/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
MOAT
28/100
→ Income
GROWTH
15/100
→ Income
INCOME
N/A
No coverage

Valuation Snapshot — PRDS

Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.61
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2021 $-10.14 $0.00 $-38.55M -
2022 $-1.61 $0.00 $-93.45M -
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message